Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q2 2022 Results - Earnings Call Transcript

Jul. 27, 2022 11:42 AM ETBoston Scientific Corporation (BSX) StockBSX
SA Transcripts
153.96K Followers

Q2: 2022-07-27 Earnings Summary

EPS of $0.44 beats by $0.02
 | Revenue of $3.24B (5.43% Y/Y) beats by $23.37M

Boston Scientific Corporation (NYSE:BSX) Q2 2022 Results Conference Call July 27, 2022 8:00 AM ET

Company Participants

Lauren Tengler - Vice President, Investor Relations
Mike Mahoney - Chairman & Chief Executive Officer
Dan Brennan - Executive Vice President & Chief Financial Officer
Ken Stein - Chief Medical Officer, Rhythm Management
Ian Meredith - Global Chief Medical Officer

Conference Call Participants

Joanne Wuensch - Citi
Robbie Marcus - JPMorgan
Larry Biegelsen - Wells Fargo
Vijay Kumar - Evercore
Rick Wise - Stifel
Cecilia Furlong - Morgan Stanley
Travis Steed - Bank of America
Pito Chickering - Deutsche Bank
Josh Jennings - Cowen
Richard Newitter - Truist
Jayson Bedford - Raymond James
Shagun Singh - RBC

Operator

Good morning, and welcome to the Boston Scientific Second Quarter 2022 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.

Lauren Tengler

Thank you, Andrew. Welcome, everyone, and thanks for joining us today. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and Dan Brenhan, Executive Vice President and Chief Financial Officer. We issued a press release earlier this morning announcing our Q2 2022 results, which included reconciliations of the non-GAAP measures used in the release. We have posted a copy of that release as well as reconciliations of the non-GAAP measures used in today's call to the Investor Relations section of our website under the heading Financials & Filings.

The duration of this morning's call will be approximately 1 hour. Mike will focus his comments on Q2 performance as well as future catalysts and the outlook for our business, including Q3 2022 and full year 2022 guidance. Dan will review the financials for the quarter, provide more details regarding our Q3 and full

Recommended For You

About BSX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BSX